Hepatitis C (HCV) is the most prevalent liver disease in the world. The World Health Organization considers Hepatitis C an epidemic. Because a patient living with Hepatitis C can be infected for decades before being discovered, it is often called the “silent” epidemic.
According to the Center for Disease Control (CDC), 20-30% of people with chronic Hepatitis C will eventually face life-threatening symptoms.
The cure for hepatitis C is available. The treatment used most often is a combination of two medicines, pegylated interferon and ribavirin. However, not every person with hepatitis C should be treated. Each person must be evaluated to decide if treatment is right for him/her. The decision to treat is made using results of liver tests, tests for the virus in blood (NAT), and possibly a liver biopsy. The treatment of hepatitis C is an area of active research and changes as studies are completed. Consult with a physician for the most recent recommendations on treatment. Some people may get treatment through clinical studies if they qualify for a study.
Another effective cure for hepatitis C
The cure for hepatitis C has evolved steadily since alpha interferon was first approved for use in this disease more than 10 years ago. At the present time, the optimal regimen appears to be a 24- or 48-week course of the combination of pegylated alpha interferon and ribavirin.
Alpha interferon is a host protein that is made in response to viral infections and has natural antiviral activity and hence is cure for hepatitis C. Recombinant forms of alpha interferon have been produced, and several formulations (alfa-2a, alfa-2b, consensus interferon) are available as therapy for hepatitis C. These standard forms of interferon, however, are now being replaced by pegylated interferon (peginterferon).
Peginterferon is alpha interferon that has been modified chemically by the addition of a large inert molecule of polyethylene glycol. Pegylation changes the uptake, distribution, and excretion of interferon, prolonging its half-life. Peginterferon can be given once weekly and provides a constant level of interferon in the blood, whereas standard interferon must be given several times weekly and provides intermittent and fluctuating levels. In addition, peginterferon is more active than standard interferon in inhibiting HCV and yields higher sustained response rates with similar side effects. Because of its ease of administration and better efficacy, peginterferon has replaced standard interferon both as monotherapy and as combination cure for hepatitis C.
The herb is commonly known as stonebreaker because of its strong roots that are capable to cure biliary diseases. It is beneficial in cough, asthma, urinary diseases, jaundice, malaria and enlargement of liver and spleen
Some of the prime indications for Bhumyamlaki include –
* The best hepatic supportive drug
* Biliary diseases
G-LIV is an all-natural blend of herbal extracts found to protect and restore the function of your liver while balancing your immune system. Also helps to protect the liver from damage associated with autoimmunity, inflammation, oxidation, and infections such as hepatitis viruses. It is useful in:
* Alcoholic liver disease
* Cirrhosis of liver